Clinigen divests Proleukin® to Iovance Biotherapeutics for £166.7 million

23 January 2023 Clinigen divests Proleukin® to Iovance Biotherapeutics for £166.7 million The deal includes a £41.7 million milestone payment and double-digit Proleukin® global sales royalties Clinigen Limited (‘Clinigen’) (‘the Company’), the global pharmaceutical services company, has entered into an agreement to divest Proleukin® (interleukin-2 (aldesleukin)), to Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) (‘Iovance’), a late-stage […]

Read More

Topps Tiles Transforms Fleet Delivery Operations and Strategic Modelling with Descartes’ Route Optimisation Solution

LONDON and ATLANTA, Jan. 23, 2023 (GLOBE NEWSWIRE) — Descartes Systems Group (Nasdaq: DSGX) (TSX:DSG), the global leader in uniting logistics-intensive businesses in commerce, announced that Topps Tiles, the leading U.K. tile retailer, is optimising its fleet delivery capabilities with Descartes’ cloud-based route planning and optimisation solution. By working with Descartes, Topps Tiles is decreasing […]

Read More

Wistar Institute HIV Researchers Win Grant to Explore Genetically Engineered Natural Killer Cells as HIV Therapy

PHILADELPHIA, PA, Jan. 19, 2023 (GLOBE NEWSWIRE) — amfAR, The Foundation for AIDS Research, has awarded Luis J. Montaner, D.V.M., D.Phil., in collaboration with Mohamed Abdel-Mohsen, Ph.D., a Target Grant for $397,663 over two years. Montaner, who leads The Wistar Institute’s HIV Research Program, is studying the ability of a type of immune cell known […]

Read More
Back To Top